Search

Displaying results 5211 - 5220 of 10000 in total
  1. Drug

    DADLE

    go.drugbank.com/drugs/DB08856
    Experimental

    It can cause transient depression of mean arterial blood pressure and heart rate.

  2. Drug

    Ganstigmine

    go.drugbank.com/drugs/DB06525
    Experimental

    Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.

  3. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

    Categories: Topoisomerase II Inhibitors
  4. Drug

    alpha-methylthiofentanyl

    go.drugbank.com/drugs/DB01470
    ExperimentalIllicit

    alpha-methylthiofentanyl is an opioid analgesic that is an analog of fentanyl.

  5. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  6. Drug

    Transcrocetinate

    go.drugbank.com/drugs/DB05974
    Investigational

    Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  8. Drug

    Mimopezil

    go.drugbank.com/drugs/DB05520
    Experimental

    Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.

  9. Drug

    Rimtuzalcap

    go.drugbank.com/drugs/DB16733
    Investigational

    Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.[L38414]

  10. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.